Narcan Nasal Product

PreclinicalSmall molecule

JJohns Hopkins Bloomberg School of Public Health

Narcan Nasal Product is one of 7 small molecule programs targeting Overdose. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OverdoseActive, not recruiting

OverdosePreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Overdose

#DrugCompanyPhaseTrials

Narcan

SScienture

Approved

2 2

Suboxone

Glucophage

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

—5

Buprenorphine/naloxone

Astellas

Preclinical

—6

VORAXAZE

BBTG International Inc.

Preclinical

1 7

Narcan Nasal Product

JJohns Hopkins Bloomberg School of Public Health

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Overdose1 trial

An Evaluation of a Social Network Intervention for Primary and Secondary Prevention of Opioid Overdoses

Completed·JJohns Hopkins Bloomberg School of Public Health·N/A·NCT04212364·614 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Narcan Nasal Product. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Narcan Nasal Product compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Narcan Nasal Product. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johns Hopkins Bloomberg School of Public Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: JJohns Hopkins Bloomberg School of Public Health

Narcan Nasal Product

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Overdose1 trial

References

Drug Info

Quick Facts

Related News